Please go to the PowerPak homepage
and select a course.
Optimizing the Hospital Pharmacist’s Role in the Management of Patients with Acute Severe Hypertension
October 13, 2020
October 13, 2021
This CE program will highlight the hospital pharmacist’s role in the management of patients with acute severe hypertension. The expert faculty, led by Paul Szumita, PharmD, will discuss the physiological mechanisms involved in the development of hypertension, global occurrence, and burden of disease for affected individuals. The faculty will review the latest evidence-based data on approaches and techniques for identification and treatment interventions to improve the management of patients with acute severe hypertension. The current standards of care for the management of acute severe hypertension in adults across multiple disease states will be discussed. Finally, the expert faculty will review management approaches to capitalize on the important role of the hospital pharmacist within the healthcare team for optimal care of patients with acute severe hypertension. Upon completion of this activity, learners will gain further insight into optimal management strategies for patients with acute severe hypertension.
Hospital pharmacists, physicians, nurse practitioners, nurses, physician assistants and other healthcare professionals involved in the management of patients with acute severe hypertension
- Introduction and Welcome, Review Objectives
- A Trialist’s Perspective on Acute Severe Hypertension: A Review of Science, Pathophysiology, Data, by Drug Class
- Case Vignettes on the Challenges of Acute Severe Hypertension
- Acute Stroke at a Spoke Hospital
- Aortic Dissection in the ED
- Acute Severe Heart Failure in the CCU
- The Latest Evidence Supporting Parenteral Antihypertensive Therapeutic Options
- Management Approaches to Capitalize on the Important Role of the Pharmacist for Optimal Patient Care
- Emergency Management
- Transition to Improved Chronic Management
- Patient Education to Reduce the Risk of Recurrent ASH
- Faculty Panel Discussion
- Review the physiological mechanisms involved in development of hypertension, global occurrence, and burden of disease for affected individuals, including cardiovascular risk factors
- Examine the latest evidence-based data on optimized approaches and techniques for identification and treatment interventions to improve the management of patients with acute severe hypertension
- Discuss the current standard of care for the management of acute severe hypertension in adults across multiple acute disease states
- Discuss management approaches to capitalize on the important role of the hospital pharmacist within the healthcare team for optimal care of patients with acute severe hypertension
Paul M. Szumita, PharmD, FCCM, FASHP, BCCCP, BCPS
Clinical Pharmacy Practice Manager
Program Director- PGY2 Critical Care Pharmacy Practice Residency
Brigham and Women’s Hospital
Megan E. Barra, PharmD, BCPS, BCCCP
Attending Pharmacist, Neurocritical Care
Massachusetts General Hospital
Department of Pharmacy
James F. Gilmore, PharmD, BCCCP, BCPS
Adult Critical Care and Emergency Department
Los Angeles, CA
Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Department of Emergency Medicine
University of Mississippi School of Medicine
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Relationship Identified With
|Paul M. Szumita, PharmD
|Nothing to disclose
|Megan E. Barra, PharmD
|Nothing to disclose
|James F. Gilmore, PharmD
|Nothing to disclose
|Charles V. Pollack Jr., MA, MD
|Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals
Grant/Research Support: AstraZeneca Pharmaceuticals
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 1.5 CNE Contact Hours, including 1.5 pharmacotherapeutic contact hours (Provider number P0491).
AcademicCME designates this continuing education activity for 1.5 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credits (UAN # JA4008190-0000-20-013-H04-P).
This activity has been supported by an independent educational grant from Chiesi USA, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Chiesi USA, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a "certificate of completion".
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact firstname.lastname@example.org.